Prevention of HIV/AIDS

Somerset Island Prep Holds Class of 2020 Commencement on Jet Skis

Thursday, May 28, 2020 - 11:17pm

The idea to have a Jet Ski graduation is a perfect example of the innovative mindset which permeates Somerset Island Prep.

Key Points: 
  • The idea to have a Jet Ski graduation is a perfect example of the innovative mindset which permeates Somerset Island Prep.
  • View the full release here: https://www.businesswire.com/news/home/20200528005860/en/
    Somerset Island Prep senior jet skis to collect his diploma off the Key West coast.
  • (Photo: Business Wire)
    Tuesday evening, the SIP Class of 2020 jet skied in front of Key Wests Southernmost House.
  • Somerset Island Prep was recently ranked on US News & World Reports 2020 Best High Schools list.

Texas Health Action partners with MISTR to expand access to HIV prevention across Texas

Thursday, May 28, 2020 - 5:11pm

AUSTIN, Texas, May 28, 2020 /PRNewswire/ -- Texas Health Action (THA), a nonprofit dedicated to advancing sexual wellness in Texas, is expanding access to HIV prevention medication across the state through a partnership with MISTR, an online telemedicine company.

Key Points: 
  • AUSTIN, Texas, May 28, 2020 /PRNewswire/ -- Texas Health Action (THA), a nonprofit dedicated to advancing sexual wellness in Texas, is expanding access to HIV prevention medication across the state through a partnership with MISTR, an online telemedicine company.
  • "This innovative partnership allows us to quickly expand HIV prevention through PrEP across the state," Christopher Hamilton, chief executive officer of THA, said.
  • Patients can access a licensed physician who specializes in HIV preventative care through the MISTR and SISTR platforms.
  • "We hope this partnership will allow even more people to access this vital component in the fight against HIV."

Scientists Uncover Ways HIV is Sexually Transmitted in Women

Wednesday, May 27, 2020 - 1:01pm

HIV is known to home in on a special type of immune cell called a CD4+ T cell.

Key Points: 
  • HIV is known to home in on a special type of immune cell called a CD4+ T cell.
  • "We still lack a fundamental understanding of the features of cells that first become infected upon HIV transmission in women," says Roan, who is also professor of urology at UC San Francisco.
  • "Our findings mayhelp explain the inconsistent effectiveness of oral PrEP or microbicides in protecting women from sexual transmission of HIV."
  • Scientists can now use these findings to develop strategies that could stem the ability of sexually transmitted HIV to infect women.

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

AHF Welcomes ViiV’s Success with Injectable HIV Prevention Medication

Wednesday, May 20, 2020 - 9:14pm

The company announced results of an interim analysis Sunday evening, also reporting that it would end the global study of its new HIV prevention medication early and offer all study participants access to CAB LA.

Key Points: 
  • The company announced results of an interim analysis Sunday evening, also reporting that it would end the global study of its new HIV prevention medication early and offer all study participants access to CAB LA.
  • As an injectable, two-month dosed medication thats demonstrated significantly greater efficacy than the current form of pre-exposure prophylaxis, cabotegravir offers an exciting way forward to far simpler and more effective HIV prevention.
  • Cabotegravir looks to be an exciting new addition to the world of HIV prevention.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

FRC Releases New Publication Showing Extent of Radical Sex Education in Schools

Wednesday, May 20, 2020 - 7:01pm

WASHINGTON, May 20, 2020 /PRNewswire/ -- Family Research Council released a new publication today titled " Sex Education in Public Schools: Sexualization of Children and LGBT Indoctrination ."

Key Points: 
  • WASHINGTON, May 20, 2020 /PRNewswire/ -- Family Research Council released a new publication today titled " Sex Education in Public Schools: Sexualization of Children and LGBT Indoctrination ."
  • It outlines the radical changes that have occurred in the way sex education is taught in America's public schools, and why parents should be concerned:
    Teaching kids how to consent to sex/"how to" sex workshops.
  • "Fake Abstinence"abstinence until your next steady boy/girlfriend.
  • School systems are devoting significant classroom time to these programs70 classroom hours per child in some caseseven while American public schools are failing to fulfill their core mission.

SARS-CoV-2 Replication Process Depiction Explains Drug and Vaccine Opportunities

Wednesday, May 20, 2020 - 1:05pm

"By sharing this depiction of the disease mechanism and the body's response, we hope it supports a cure or treatment options for COVID-19."

Key Points: 
  • "By sharing this depiction of the disease mechanism and the body's response, we hope it supports a cure or treatment options for COVID-19."
  • Force also created a comprehensive resource of drugs and vaccines under investigation for COVID-19.
  • Detailed information includes drug class and name; combination/comparator drugs; and clinical trial number, sponsorship or collaboration, overview, format, test population, start and end dates and location.
  • Access the virus depiction and resource for drug and vaccine investigations underway for COVID-19 treatment and prevention at http://www.forcemed.com/services/lifecycle and http://www.forcemed.com/services/resources respectively.

CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir

Monday, May 18, 2020 - 11:00am

Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.

Key Points: 
  • Leronlimab was administered to more than sixty patients with COVID-19 under emergency Investigational New Drug (eINDs) authorizations granted by the FDA.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer.

Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Monday, May 18, 2020 - 7:17am

The study achieved its primary objective of non-inferiority with the difference approaching superiority in favour of cabotegravir, pending final analysis.

Key Points: 
  • The study achieved its primary objective of non-inferiority with the difference approaching superiority in favour of cabotegravir, pending final analysis.
  • Despite this high level of adherence to oral therapy, long-acting cabotegravir was 69% (95% CI 41%-84%) more effective than FTC/TDF in preventing HIV acquisition in the study population.
  • To lower that number, we believe more prevention options are needed in addition to currently available oral tablets for daily use.
  • New options are needed for HIV prevention that offer an effective alternative to daily oral PrEP.

CytoDyn Clarifies Status of Biologics License Application

Saturday, May 9, 2020 - 12:59am

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.

Key Points: 
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients.
  • CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.